Background: Application of next-generation DNA sequencing (NGS) has recently become increasingly common in the field of clinical oncology in several countries around the world. In Japan also, a system for applying NGS to routine clinical practice is gradually being established. During this process, we introduced in Japan the tumor-profiling MSK-IMPACT (Memorial Sloan KetteringIntegrated Mutation Profiling of Actionable Cancer Targets) assay. Methods: We present here our initial experience with the use of MSK-IMPACT in 68 patients selected from two institutions in Japan between June 2016 and October 2017. Results: MSK-IMPACT sequencing was successful and yielded results in specimens obtained from 64 of the 68 patients, representing an overall assay success rate of 94.1%. The top three cancer types tested were endometrial cancer (17.2%), pancreatic cancer (15.6%) and colorectal cancer (12.5%). Evaluation of the clinical actionability of the genetic alterations revealed that 25.0% of patients (n = 16) harbored at least one actionable alteration. However, enrolling the patients in a genomically matched clinical trial was difficult, mainly because most clinical trials are limited to tumors arising from a specific organ/site. One patient with microsatellite instability-high status, as determined by MSK-IMPACT, was treated with pembrolizumab and showed partial response. Conclusions: Although tumor profiling by NGS and administration of genomically matched therapy is a promising strategy, because of its high cost, we need to consider how we can fit it into
Introduction
Since genetic alterations in normal cells are the fundamental cause of cancer, the strategy to identify genetic alterations in cancer cells and use suitable drugs against the detected genetic alterations has become a standard clinical strategy. Multiple tumor-profiling nextgeneration sequencing (NGS) panels have been developed, with some being currently available for clinical testing and covered by health insurances. Among these multiple panels, the US Food and Drug Administration (FDA) announced the clearance and authorization of MSK-IMPACT (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets), a highthroughput, targeted DNA sequencing panel for somatic mutations, in November 2017. Thus, MSK-IMPACT is the first tumor-profiling laboratory-developed test (LDT) established in an academic medical center to receive authorization from the FDA.
MSK-IMPACT is a hybridization capture-based NGS panel that was developed by the Department of Pathology and the Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center (MSKCC), New York. Using Formalin-Fixed Paraffin-Embedded (FFPE) tumor specimens and matched normal DNA, all protein-coding mutations, copy number alterations (CNAs), and selected promoter mutations and structural rearrangements in the 468 cancer-associated genes included in the panel can be detected (1) . The sequence mutations, CNAs and rearrangements detected by MSK-IMPACT are annotated according to OncoKB (http://oncokb.org/) (2), which is a curated knowledge base of the oncogenic effects and treatment implications of somatic mutations.
In Japan, tumor profiling using NGS panels has been performed as part of basic research or in clinical trials, such as the LC-SCRUM-Japan project for lung cancer. However, when the clinical sequencing is conducted as part of a study, patients who do not meet the inclusion criteria for the study cannot undergo the clinical sequencing, even if they so desire. In April 2015, Kyoto University Hospital introduced, for the first time, clinical sequencing using an NGS-based multiplex gene assay (OncoPrime) for daily clinical practice in Japan (3) . While the burden of the expense falls on the patient, because clinical sequencing in daily clinical practice is currently not covered by health insurance in Japan, it could benefit those patients who wish to have their tumor submitted for clinical sequencing.
In June 2016, through an agreement between MSKCC and TailorMed (Tokyo, Japan), we introduced MSK-IMPACT for clinical testing in Juntendo University Hospital. Subsequently, in November 2016, we also introduced it in Yokohama City University Hospital. Herein, we report the results of analysis of the first 68 Japanese cases tested using MSK-IMPACT. This is the first report of clinical experience in Japan with the FDAcleared NGS-based multiplex gene assay, by which alterations in more than 400 genes can be analyzed using matched normal tissue samples. Furthermore, this is the first report of MSK-IMPACT sequencing of a cohort of samples collected from outside the USA.
Materials and Methods

Patients
This was a multicenter retrospective observational study of the results of MSK-IMPACT sequencing conducted in the initial 64 cases in Japan from 1 June 2016 to 31 October 2017. Patients with histopathologically confirmed solid tumors at Juntendo University Hospital or Yokohama City University Hospital were offered to have their tumor sent to MSKCC for MSK-IMPACT sequencing. This study was conducted with the approval of the Ethics Committees of both the Juntendo University Graduate School of Medicine (2016044) and the Yokohama City University Graduate School of Medicine (A160728006). We registered this study with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000031407). Written informed consent for use of the genomic and clinical data for research purposes was obtained from all the patients.
Workflow of MSK-IMPACT in Japan
After MSK-IMPACT sequencing was requisitioned by the treating physician, 20 slices of 5-μm sections of the FFPE tumor tissue specimens and matched normal tissue specimens were shipped to MSKCC, through a distributor in Japan (TailorMed, Tokyo, Japan). When we could not arrange matched normal tissue samples, we prepared FFPE cell blocks of the patient's peripheral blood using Lymphoprep™ (Alere Technologies AS) and iPGell™ (Genostaff, Tokyo, Japan), in accordance with the manufacturer's protocol. The methodology of the MSK-IMPACT assay has been described previously (4). Briefly, DNA isolated from tumor tissue and matched normal tissue specimens was subjected to hybridization capture and deep-coverage NGS to detect somatic mutations, small insertions and deletions, CNAs and chromosomal rearrangements in 468 cancer-associated genes. All results were reviewed by a team consisting of bioinformaticians, molecular pathology fellows and attending molecular pathologists, and the final report signed by the pathologist was sent to TailorMed.
In the MSK-IMPACT sequencing workflow, the quality of the samples is checked before sequencing. First, hematoxylin and eosin (H&E) stained slides are reviewed by a pathologist, and samples with low tumor purity (<10%) are excluded. Second, DNA yield is quantified after DNA extraction, and samples with insufficient DNA yield (<50 ng) are not processed further for MSK-IMPACT. Additionally, after sequencing, the data are checked for deficiencies in multiple quality control metrics, including insufficient average unique sequence coverage (<100X), biases in coverage distribution and possibility of sample contamination.
After the final report from MSKCC was received by TailorMed, the report was translated into Japanese (TailorMed, Tokyo, Japan), and the original English report and Japanese translation were sent to the requisitioning physician. The data were also uploaded to an online dataset available through the cBioPortal for Cancer Genomics (http://cbioportal.org/msk-impact) (5) .
Clinical assessment
Sequence mutations, CNAs and rearrangements detected by MSK-IMPACT sequencing were annotated according to the original database created by MSKCC, called OncoKB (http://oncokb.org/) (2). In the OncoKB knowledge base, the genetic alterations are classified into stepwise categories (levels) according to the strength of evidence to suggest whether they can serve as predictive biomarkers of the drug response. Level 1 includes genetic alterations that are FDArecognized biomarkers. Level 2 includes genetic alterations that are biomarkers recommended as standard care by the National Comprehensive Cancer Network (NCCN) or other expert panels. Level 3 includes genetic alterations that predict response to investigational agents in clinical trials. Level 4 includes genetic alterations that have hypothetical therapeutic implications based on preliminary, non-clinical data.
Tumor samples were annotated according to the highest level of evidence for any mutation identified by MSK-IMPACT sequencing (6) . Additionally, the microsatellite instability (MSI) status was assessed using the MSIsensor program (7) that interrogates the length distribution of all genomic microsatellite loci included in the MSK-IMPACT capture region across the tumor and matched normal samples. MSI status determination by MSK-IMPACT has been shown to be highly concordant with conventional MSI PCR assays and IHC for mismatch repair proteins (7). The tumor mutation burden (TMB) was evaluated by dividing the number of sequence mutations reported by the MSK-IMPACT assay by the total genomic area from which mutations were reported, according to the version of the assay that was used. Based on a previous report (4), a threshold of 13.8 mutations/Mb was considered as indicative of a high TMB.
Results
Description of the sequencing cohort
Between June 2016 and October 2017, we submitted specimens from 68 patients for MSK-IMPACT sequencing. After isolation of DNA from the tumor tissue and matched normal tissue specimens, the quality and quantity of DNA were evaluated. Three samples (4.4%) were excluded from the DNA sequencing step because of an insufficient amount of DNA available. The remaining 65 samples were submitted for sequencing, however, one of the samples (1.5%) did not meet the DNA qualitative criteria. Altogether, genomic data for final reports were successfully obtained for 64 of the 68 submitted samples (Fig. 1) . We submitted surgically resected tumor samples in most of the cases (n = 65, 95.6%), while in three (4.4%) cases, we submitted samples obtained by needle or endoscopic biopsy. Of the three biopsy specimens, two were excluded because of an insufficient amount of DNA available for sequencing, and we obtained genomic data for the remaining one. The distribution of the tumor types among the 64 cases that were successfully sequenced is shown in Fig. 2 . The top three types of cancer specimens that were submitted were specimens of endometrial cancer (17.2%), pancreatic cancer (15.6%) and colorectal cancer (12.5%).
Tumors were sequenced to deep coverage (average = 621.6×, range 187-1063), and mutations were determined against the patients' matched normal samples. Altogether, we detected 368 non-synonymous mutations, 96 CNAs, and 21 rearrangements. In addition, two samples were concluded as showing MSI using MSI sensor ( Table 1 ).
Distribution of somatically altered genes
The online dataset of MSK-IMPACT, called cBioPortal, helps in visualization of all the data. As shown in Fig. 3 , we could create a compact graphical summary of the genomic alterations in multiple genes across a set in our study using 'OncoPrint,' which is one of the online tools in cBioPortal (5, 8) .
The most frequently altered gene in our cohort was TP53 (61.3% of the specimens), and all the detected mutations were annotated in OncoKB. Of the total, 41.7% of the mutations were truncations, and 50.0% were missense mutations, which are annotated as inactivating. Using one of the online tools of cBioPortal called 'Mutation mapper,' we could also create a graphical summary of the genomic alterations in selected genes. For example, the TP53 mutations in our cohort are summarized in Fig. 4 .
KRAS was the second most frequently altered gene (27.0% of the specimens). All detected mutations other than KRAS D54Gfs*33 Figure 1 . Success rate of MSK-IMPACT assay in Japan. A total of 68 tumor samples were submitted from Japan for MSK-IMPACT sequencing between June 2016 and October 2017. After DNA extraction and quantification, the DNA yield was found to be insufficient (<50 ng) in four cases, in which sequencing was therefore not performed. Out of the 65 sequenced cases, one failed one of multiple quality control metrics, including the average unique sequence coverage (<50×), and showed biased coverage distribution and evidence of sample contamination. Finally, successful sequencing was accomplished in 64 cases, representing a final assay success rate of 94.1%. were also annotated in OncoKB. Of the mutations, 70.6% were detected in codon 12 (G12), which was the most frequently altered codon in our cohort. Mutations of codon 12 in KRAS were detected in 18.8% of all the specimens in our cohort.
PIK3CA was the third most frequently altered gene (14.3% of the specimens). PIK3CA mutation mostly frequently occurred in uterine cancer (50.0%) and breast cancer (40.0%) in our cohort.
Genomic rearrangements
Genomic rearrangements were identified in 16 specimens (25.0%). It has been reported that certain gene fusions are detected in a subset of particular lineages, such as ASPSCR1-TFE3 gene fusions in renal cell carcinoma (RCC) (9) . In our cohort, we detected this fusion gene in a patient with RCC.
TERT promoter mutations
In addition to the coding regions of the cancer-associated genes, MSK-IMPACT also captures the promoter of TERT, which is frequently mutated in human cancer (4) . In out cohort, TERT promoter mutations were detected in five patients (7.8%). The cancer types in which they were found were oral cavity squamous cell carcinoma, adenosquamous carcinoma of the tongue, head and neck squamous cell carcinoma, prostate adenocarcinoma and glioblastoma multiforme.
MSI status and tumor mutation burden
MSI status and TMB have recently been reported as being important for predicting responses to immune checkpoint inhibitors. In our cohort, microsatellite instability-high (MSI-H) status was detected in two patients with endometrial cancer. Both of the patients with MSI-H were also considered as showing a high TMB; the mutation counts /Mb were 53.3 and 14.0, respectively.
Clinical actionability
According to OncoKB, we evaluated the clinical actionability of the detected genomic alterations in each patient. Altogether, 25.0% of the patients (n = 16) harbored contained at least one actionable alteration (Fig. 5) . The actionable mutations detected in our cohort are summarized in Table 2 . In addition, we detected some variants of unknown significance (VUS) in some druggable genes, which are summarized in Table 3 .
One patient with MSI-H was treated with pembrolizumab and showed partial response. The patient was a 60-year-old woman with uterine neuroendocrine carcinoma with multiple lung and lymph node metastases. MSK-IMPACT revealed that over 20 genes were mutated, including KRAS, PIK3CA, PTEN. TMB of this case was 18.4/Mbp (>13.8), and the MSIsensor score was high at 19.8 (>10), indicating that this tumor was TMB-High as well as MSIHigh. Because this case was resistant to prior combination therapy including platinum derivative, she was treated with pembrolizumab. After administration of three cycles of pembrolizumab, significant reduction of mediastinal lymph nodes was observed (Fig. 6) .
The other two patients with Level 1 genetic alterations, as well as the two patients with Level 2 genetic alterations are receiving standard therapy at this point. Although the drugs for Level 3 alterations are mostly under investigation in clinical trials, the level of evidence is expected to increase for some of them based on the outcome of these trials. Since the OncoKB database is continually being updated, we propose to also update our patients when new information is obtained in the future.
Discussion
We have reviewed our initial experience of MSK-IMPACT sequencing in 68 cancer patients from two institutions in Japan between June 2016 and October 2017. Of the 68 submitted samples, final reports with genomic data were successfully generated for 64 samples. The top three types of cancer specimens submitted were specimens of endometrial cancer (17.2%), pancreatic cancer (15.6%) and colorectal cancer (12.5%). The most frequently altered gene in our cohort was TP53 (61.3% of the specimens), followed by KRAS (27.0% of the specimens). Genomic rearrangements were reported in 16 specimens (25.0%), and TERT promoter mutations in five specimens (7.8%). In addition, MSI-H was detected in two specimens, of which one was also considered to show a high TMB. In terms of the clinical actionability of the detected genomic alterations, 54.7% of the patients (n = 25) harbored at least one actionable alteration, and one patient received a new therapy based on the results of MSK-IMPACT sequencing.
Both the quantity and quality of the samples are important for obtaining appropriate results of clinical sequencing. Although previous studies demonstrated that small samples such as needle biopsy and cytologic samples could provide adequate DNA for MSK-IMPACT sequencing (10, 11) , the overall success rate was the highest in surgical resections (94%), followed by biopsies (82%) and cytology samples (76%) (4) . Thus, we mainly submitted surgically resected specimens. However, for unresectable cancer patients, the capability for performing sequencing in small amounts of samples is essential. In our cohort, two biopsy specimens, while we judged that there was a sufficient amount of tumor cells, the samples did not meet the criteria of DNA quantity and quality for the sequencing step in the MSK-IMPACT assay. Based on the experience in these two cases, in the third case of needle biopsy, we sent the entire paraffin block, and DNA extraction and sequencing were successful.
In terms of the sample quality, overfixation due to long immersion in formalin was a problem. In one of the samples fixed by immersion in formalin for seven days, sequencing failed because of insufficient DNA. Based on our experience of this case, we now confirm the date of surgery and the date of acceptance of the specimen at the Figure 4 . Genomic alterations in TP53 detected by MSK-IMPACT sequencing in Japan. A graphical summary of the genomic alterations TP53 detected in our cohort was created using Mutation mapper, one of the online tools in cBioPortal. The mutations were classified into four groups; missense, truncating, in-frame and other. pathology department. The Japanese Society of Pathology published a guideline for appropriate treatment of pathological tissue specimens for genomic diagnosis in March 2018, in which they recommend fixation in formalin for no longer than 3 days. Moreover, MSKCC recommends the fixation less than 1 day. The purpose of MSK-IMPACT sequencing for patients is to discover new therapeutic options for their cancer. In our cohort, 54.7% of the patients (n = 35) harbored at least one actionable alteration (Fig. 5) . In the classification of the evidence level in OncoKB, evidence Levels 1-3 indicate clinical evidence, whereas Level 4 indicates evidence based on non-clinical data. In our cohort, we detected Levels 1-3 genetic alterations in 25.0% of the tumor specimens (n = 16).
Because we accepted requests for MSK-IMPACT regardless of the type of advanced cancer, our dataset contains a small number of diverse cancer types. Although it is difficult to conclude which types of cancers are most suitable for large panel next-generation sequencing, patients with endometrial cancer are clearly good candidates. Comparing the top two types of cancer specimens in our cohort, 45.5% (5/11) of endometrial cancer had Levels 1-3 genetic alterations, whereas 0% (0/10) of pancreatic cancer had such alterations.
We detected three cases with Level 1 genetic alterations in their cancers. One of the patients had an EGFR mutation. EGFR is one of the good targets for genomically matched therapy, because mutated variants of this gene are well annotated, and the safety and efficacy of multiple targeted drugs have been well studied. We detected the mutation EGFR L858R in a patient with non-small cell lung cancer.
L858R is one of the clinically validated variants of EGFR, that has been reported to result in gain of function (12) (13) (14) . Three drugs, gefitinib, erlotinib, afatinib and osimeritinb have been approved in Japan based on Level 1 evidence for patients with non-small cell lung cancer harboring this mutation (15) (16) (17) (18) (19) (20) (21) (22) (23) . Determination of the MSI status is important for predicting the response to immune checkpoint inhibitors. In the MSK-IMPACT assay, the MSI status is assessed using the MSIsensor program (7) . It has been reported that evidence of MSI at 10% or more of the analyzable loci (MSIsensor score) is highly consistent with MSI-H and mismatch repair deficiency (MMR-D) (24) . Notably, MSI-H is approved as a Level 1 biomarker for predicting the response to pembrolizumab in cases of solid tumors regardless of specific type or histology, based on a clinical trial conducted in patients with multiple types of solid tumors (25) . In our cohort, one of the two patients with MSI-H was treated with pembrolizumab and showed partial response (Fig. 6 , Terao et al. case report in preparation). For the other patient with MSI-H, as there were other therapeutic options that represented standard therapy at that point, we did not recommend use of immune checkpoint inhibitors.
In addition to the MSI status, the TMB is considered to be a promising biomarker for predicting the response to immune checkpoint inhibitors (26) (27) (28) . Although TMB was originally assessed by whole-exome sequencing (WES), it has been reported that it can also be analyzed from targeted capture data. In regard to the usefulness of the MSK-IMPACT platform for determining the TMB, a comparison of the results of MSK-IMPACT sequencing and matched WES data from 106 tumors revealed a high correlation (R 2 = 0.76) (4). When using TMB as a biomarker, determining the appropriate cutoff value is critical but can be challenging. In a previous report of 10,000 tumors studied by MSK-IMPACT sequencing, the threshold for identifying highly mutated tumors was calculated using the following formula: median (TMB) + 2 × IQR(TMB), where IQR is the interquartile range (4). Since the threshold of 13.8 mutations/Mb was calculated from a sufficiently large number of MSK-IMPACT samples, we used it to define TMB in this cohort. However, TMB is still an investigational biomarker which will require further evaluation prior to application in routine clinical practice. The comparison of our Japanese patients' data and the previous report about the MSK-IMPACT (4) would be important for suitable design of clinical trials for Japanese patients. Although the sample size is small in our cohort, the distribution of genetic alterations in the tumors studied in our Japanese cohort are not much different from the result of 10 000 patients in the USA. However, it should be noted that lung adenocarcinomas, a cancer type with much more frequent EGFR mutations in Asian versus non-Asian populations, were underrepresented in our cohort, most likely because they are already captured by routine EGFR testing in Japan. For comprehensive analysis of genetic alterations in tumors from Japanese patients, not only further sequencing additional samples, but also establishment of a system that collects Japanese patient tumor sequencing data will be important.
In our experience of managing clinical sequencing in Japan, we have faced several questions as well as problems. First, the pace at which novel treatments are implemented can be slow. One possible way to increase the proportion of actionable alterations would be to establish a system to analyze the functions of the detected VUS in the druggable genes. Second, the usefulness of the results of sequencing may be reduced by intratumoral heterogeneity, heterogeneity between different primary and metastatic sites, and heterogeneity arising over time or under treatment selection. Third, although analysis of MSK-IMPACT sequencing data for germline mutations (29, 30 ) has so far not been offered in Japan, some patients are desirous of knowing whether they have a germline predisposition to their cancer. We refer such patients for genetic counseling at the respective institutions. Finally, it was difficult to enroll the patients in a genomically matched clinical trial, mainly because most clinical trials are limited to tumors arising from a specific organ/site. More basket trials which allow the study of the same molecular therapeutic target across different tumors or histologic types within a single study are needed in Japan. To overcome these challenges, multi-disciplinary collaboration and coordination will be needed, including basic scientists, pathologists, clinical geneticists, clinical trial consultants and oncologists. 
